S1 Episode 2: What's Next? Promising Trials and Therapeutics in Myelofibrosis

Join Drs Tania Jain and Aaron Gerds as they discuss the latest developments in clinical trials and investigational therapeutics for MPNs.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999594. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Primary Myelofibrosis https://emedicine.medscape.com/article/197954-overview

Myeloproliferative Neoplasms https://www.ncbi.nlm.nih.gov/books/NBK531464/

Bromodomain and Extraterminal (BET) Proteins: Biological Functions, Diseases, and Targeted Therapy https://pubmed.ncbi.nlm.nih.gov/37926722/

Long-Term Survival in Patients Treated With Ruxolitinib for Myelofibrosis: COMFORT-I and -II Pooled Analyses https://pubmed.ncbi.nlm.nih.gov/28962635/

Rampal RK, Grosicki S, Chraniuk S, et al. Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naïve patients with myelofibrosis: results of the MANIFEST-2 randomized, double-blind, phase 3 study. Program and abstracts of the 65th American Society of Hematology Annual Meeting and Exposition; December 10, 2023; San Diego, California. Abstract 628. https://ash.confex.com/ash/2023/webprogram/Paper179141.html

Pemmaraju N, Mead AJ, Somervaille T CP, et al.Transform-1: A randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis. Program and abstracts of the 65th American Society of Hematology Annual Meeting and Exposition; December 10, 2023; San Diego, California. Abstract 620. https://ash.confex.com/ash/2023/webprogram/Paper173509.html

Defining Disease Modification in Myelofibrosis in the Era of Targeted Therapy https://pubmed.ncbi.nlm.nih.gov/35499819/

A Prognostic Model to Predict Survival After 6 Months of Ruxolitinib in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35130339/

Imetelstat in Patients With Lower-Risk Myelodysplastic Syndromes Who Have Relapsed or Are Refractory to Erythropoiesis-Stimulating Agents (IMerge): A Multinational, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/38048786/